SCHEMBL210315

SCHEMBL210315

NC(CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.62
DPP4 P27487 1/20 0.53
DPP8 Q6V1X1 1/20 0.53
DPP9 Q86TI2 1/20 0.53
PTGS1 P23219 1/20 0.52
GSTK1 Q9Y2Q3 1/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GSR P00390 1/20 0.52
CYP1A2 P05177 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536354 1.00 FOLH1 (0.62) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL15420942 1.00 FOLH1 (0.62) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL210006 1.00 FOLH1 (0.62) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL15420941 1.00 FOLH1 (0.62) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL27611010 0.97 FOLH1 (0.58) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL27611015 0.97 FOLH1 (0.58) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL16770243 0.97 FOLH1 (0.58) FOLH1DPP4DPP8DPP9PTGS1
Glycine SCHEMBL343653 0.95 FOLH1 (0.57) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL9760353 0.95 FOLH1 (0.61) FOLH1DPP4DPP8DPP9PTGS1
SCHEMBL30382437 0.95 FOLH1 (0.61) FOLH1DPP4DPP8DPP9PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406592-A2 A SALT/ION PAIR MEDICINAL AEROSOL FORMULATION Aeropharm Technology Incorporated (US) 2004-04-14 EP claimed
WO-2003007867-A2 A SALT/ION PAIR MEDICINAL AEROSOL FORMULATION AEROPHRAM TECHNOLOGY, INC. (US) 2003-01-30 WO claimed
EP-0604433-A4 COMPOSITION AND METHOD FOR DISEASE TREATMENT. LIFE SCIENCES TECH INC (US) 1994-10-12 EP claimed
EP-0604433-A1 COMPOSITION AND METHOD FOR DISEASE TREATMENT LIFE SCIENCES' TECHNOLOGIES, INC. (US) 1994-07-06 EP claimed
WO-1992021368-A1 COMPOSITION AND METHOD FOR DISEASE TREATMENT LIFE SCIENCES' TECHNOLOGIES, INC. (US) 1992-12-10 WO claimed
EP-4551203-A1 OPHTHALMIC IMPLANT NaCuity Pharmaceuticals, Inc. (US) 2025-05-14 EP disclosed
CN-119894506-A Ophthalmic implant 纳崔泰制药有限公司 2025-04-25 CN disclosed
WO-2024061920-A1 METHOD FOR ASSESSING THE ACTIVITY OF NICOTINAMIDE N-METHYLTRANSFERASE FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO Y POLITÉCNICO DE LA FE DE LA COMUNIDAD VALENCIANA (ES) 2024-03-28 WO disclosed
EP-4339296-A1 METHOD FOR ASSESSING THE ACTIVITY OF NICOTINAMIDE N-METHYLTRANSFERASE Fundación para la Investigación Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) 2024-03-20 EP disclosed
WO-2024011230-A1 OPHTHALMIC IMPLANT NACUITY PHARMACEUTICALS, INC. (US) 2024-01-11 WO disclosed
CN-117187199-A Glutathione synthetase with enhanced activity and application 南京朗恩生物科技有限公司 2023-12-08 CN disclosed
CN-116926024-A Glutathione synthetase with enhanced heat resistance and application 南京朗恩生物科技有限公司 2023-10-24 CN disclosed
US-20090155440-A1 Salt Enhancing Compounds and Use GIVAUDAN SA (CH) 2009-06-18 US disclosed
US-20090130282-A1 Kokumi Flavour Compounds and Use GIVAUDAN SA (CH) 2009-05-21 US disclosed
WO-2009052186-A1 METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS GEORGIA TECH RESEARCH CORPORATION (US) 2009-04-23 WO disclosed
EP-1968650-A2 COMPOUNDS FOR DELIVERING AMINO ACIDS OR PEPTIDES WITH ANTIOXIDANT ACTIVITY INTO MITOCHONDRIA AND USE THEREOF University of Rochester (US) 2008-09-17 EP disclosed
US-20070298484-A1 Method and Device for Thermal Conditioning of a Cell INSILICO BIOTECHNOLOGY GMBH (DE) 2007-12-27 US disclosed
WO-2007076323-A2 COMPOUNDS FOR DELIVERING AMINO ACIDS OR PEPTIDES WITH ANTIOXIDANT ACTIVITY INTO MITOCHONDRIA AND USE THEREOF UNIVERSITY OF ROCHESTER (US) 2007-07-05 WO disclosed
WO-2006063116-A2 BIFUNCTIONAL ENZYME WITH Ϝ-GLUTAMYLEYSTEINE SYNTHETASE AND GLUTATHIONE SYNTHETASE ACTIVITY AND USES THEREOF GRIFFITH OWEN W (US) 2006-06-15 WO disclosed
EP-0315949-A2 A method for microbiological reaction IDEMITSU KOSAN COMPANY LIMITED (JP) 1989-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090130282-A1 Kokumi Flavour Compounds and Use KHK, KLK5, KCNK5 FOLH1 777/4885DPP4 1517/4885DPP8 1034/4885
US-20090155440-A1 Salt Enhancing Compounds and Use TAS1R1, TAS2R41, TAS2R40 FOLH1 651/4885DPP4 825/4885DPP8 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.